RxDoctor Payments Data

Maria Quinones, MD

Internal Medicine · West Hartford, CTNPI 1164567434

Payments from drug & device makers

$2,176in general payments, 2019–2025

Across 124 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arbor Pharmaceuticals, Inc.$549
  • AbbVie$458
  • Novo Nordisk$235
  • Amgen$218
  • Astellas Pharma US Inc$109
  • Abbott$81
  • plus $525 from 15 others

What the payments were for

  • Food & beverage$2,09196%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,176 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$17,193
Medicare patients
27
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$98,453
FarxigaDapagliflozin Propanediol49$71,174
LinzessLinaclotide38$39,072
JanuviaSitagliptin Phosphate34$34,904
MounjaroTirzepatide28$33,734
JanumetSitagliptin Phos/Metformin Hcl18$29,807
JardianceEmpagliflozin20$29,585
Janumet XrSitagliptin Phos/Metformin Hcl12$17,089
Tresiba Flextouch U-100Insulin Degludec17$15,925
XareltoRivaroxaban19$15,686
Dexlansoprazole DrDexlansoprazole31$6,871
VascepaIcosapent Ethyl12$4,456
SymbicortBudesonide/Formoterol Fumarate14$4,169
Insulin Lispro Kwikpen U-100Insulin Lispro18$4,030
Lidocaine13$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$235$98,45357 claims
MerckJanuvia, Janumet, Janumet Xr$47$81,80164 claims
AstraZenecaFarxiga, Symbicort$73$75,34363 claims
AbbVieLinzess, Synthroid$458$40,67351 claims
Lilly USA, LLCMounjaro$36$33,73428 claims
Boehringer IngelheimJardiance$30$29,58520 claims
Johnson & JohnsonXarelto$34$15,68619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →